Inova Diagnostics, Inc., San Diego, CA, USA.
Department of Medicine, McGill University, Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montréal, Quebec, Canada.
Autoimmun Rev. 2020 Aug;19(8):102583. doi: 10.1016/j.autrev.2020.102583. Epub 2020 Jun 14.
Systemic sclerosis (SSc) is a rare chronic disease of unknown etiology characterized by vascular abnormalities and fibrosis involving the skin and internal organs, especially the gastrointestinal tract, lung, heart and kidneys. Although the disease was historically stratified according to the extent of skin involvement, more recent approaches place more emphasis on patterns and extent of internal organ involvement. Despite numerous clinical trials, disease-modifying treatment options are still limited resulting in persistent poor quality of life and high mortality. This review provides an overview of autoantibodies in SSc and novel approaches to stratify the disease into clinically actionable subsets.
系统性硬化症（SSc）是一种罕见的病因不明的慢性疾病，其特征为血管异常和纤维化，涉及皮肤和内脏器官，特别是胃肠道、肺、心脏和肾脏。尽管该疾病在历史上根据皮肤受累的程度进行分层，但最近的方法更侧重于内脏器官受累的模式和程度。尽管进行了许多临床试验，但仍缺乏疾病修饰治疗选择，导致持续的生活质量差和高死亡率。本文综述了 SSc 中的自身抗体，并介绍了将疾病分为具有临床可操作性亚组的新方法。
